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ABSTRACT 
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS). 
Dimethyl fumarate (DMF) is one of the more recent additions to a rapidly expanding treatment reper-
toire for MS. While DMF has proven beneficial for relapsing-remitting MS (RRMS) patients, its clinical 
profile in relation to current alternatives as well as its immunological effects are less known. 
The overarching aim of the thesis was to assess the clinical effects of DMF for MS patients and inves-
tigate the underlying immunological mechanisms. Since both DMF and physical exercise is known to 
elicit an antioxidative response through the transcription factor nuclear factor erythroid 2-related factor 
2 (Nrf2), we further explored their immunological commonalities. 
In Paper I, we showed that treatment discontinuations with DMF were lower than with interferons, the 
main existing initial drug choice, among newly diagnosed MS patients in Stockholm and Västerbotten 
Counties. Risks of having persistent disease activity, as shown by relapses and/or magnetic resonance 
imaging (MRI), were similar to fingolimod and natalizumab; two more recent disease modulatory ther-
apies (DMTs). The main finding of the article, however, was that the comparator treatment, rituximab 
(Mabthera®; RTX), had a superior clinical effect compared to all other DMTs in terms of both clinical 
effect and treatment discontinuation. 
In Paper II, we used Swedish nationwide data to compare DMF to interferons and glatiramer acetate, 
two common initial DMT choices, and fingolimod, which mainly is used as an escalation treatment.  
DMF proved more effective and had better drug survival in the first line comparison with interferons 
and glatiramer acetate but was less well tolerated than fingolimod when used second line. 
In Paper III, we explored the immunological mechanisms of DMF treatment in humans underlying the 
clinical effects we observed in Paper I and II. We observed that DMF increased production of reactive 
oxygen species (ROS) in monocytes and that methylation changes occurred earlier in monocytes than 
in T cells. In addition, monocyte counts and levels of oxidized fat in blood were higher among treatment 
responders compared to non-responders, supporting the notion that DMF act by increasing oxidative 
burst in myeloid cells.  
In Paper IV, we investigated the effects of aerobic exercise of moderate and high intensity on immune 
protein markers and kynurenine pathway (KP) metabolites in cerebrospinal fluid (CSF) and plasma of 
healthy participants. Participants in the high intensity group displayed changes in concentration of sev-
eral immune markers and KP metabolites in both CSF and plasma, whereas participants in the moderate 
intensity group displayed few changes, suggesting a dose-response relationship. A separate comparison 
with DMF treated MS patients revealed few overlapping immune markers despite indications of over-
lapping mechanisms. 
In conclusion, by affecting Nrf2 and oxidative burst, DMF has a unique mode of action among existing 
DMT options for RRMS, however, with limited overlap to effects mediated by physical exercise. Its 
clinical effectiveness is superior to traditional DMTs for newly diagnosed patients, but inferior to RTX. 
As an escalation DMT, it is less well tolerated than existing alternatives.  
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1 MULTIPLE SCLEROSIS 
MS is a chronic autoimmune and degenerative disease of the CNS with recurring bouts of 
inflammatory activity, over time often resulting in accumulating neurological deficit that im-
pedes activities of daily life (1). It is the most common cause of non-traumatic neurological 
deficits in young adults in Sweden, with an annual incidence of 10 per 100.000 and a preva-
lence of 189 per 100.000 with a female to male ratio of 2.3:1 (2). An estimated 2.5 million 
people are suffering from MS worldwide, with an average increase in incidence of 10.4% be-
tween 1990 and 2016 (3). The majority (85%) of incident cases of MS are in the form of RRMS, 
which is characterized by acute onsets of neurological deterioration, often debuting between 
ages 20 and 40, interleaved by varying degrees of recovery (1). Earlier findings have shown 
that about half of patients convert to secondary progressive MS (SPMS) within 15 to 20 years 
(4). SPMS is hallmarked by a steady disease progression and is usually treatment refractive in 
proportion to absence of signs of inflammatory disease activity as shown by overlaid relapses 
or accumulation of lesions on MRI. Some patients debut with this symptomatology, in which 
case it is referred to as primary progressive MS (PPMS) and constitutes about 5% of MS pa-
tients. PPMS usually debuts in middle-aged persons and is proportionally equally distributed 
between the two sexes. Life expectancy of MS patients is generally 7-14 years shorter (5,6), 
although this has been shown to be at least partially mitigated by use of DMTs (7,8).  
 
 
Figure 1. Typical disease course of patients with multiple sclerosis (MS). Clinical symptoms of MS usually present in the 
third and fourth decade, displaying wide heterogeneity although the disease is speculated to begin several years prior. The 
disease usually initially manifests as relapsing-remitting (RRMS) which later turns into a progressive accumulation of deficits. 
While inflammation dominates the early disease course, degenerative mechanisms dominate the latter.  
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2 ENVIRONMENTAL AND GENETIC RISK FACTORS FOR 
MS 
Comparing incidence rates across countries has led to the observation of a general latitudinal 
gradient of increasing disease occurrence both north and south of the equator (9), although with 
debated exceptions within Western Europe, North America and parts of the Mediterranean 
(10,11). There is also generally a higher incidence in Western countries compared to Asia, 
Oceania and Africa (10). Potential underlying factors to this gradient include UV-exposure, 
vitamin D and melatonin levels. Low levels of UV-exposure, dietary vitamin D and vitamin D 
in serum have been associated with an increased risk of developing MS (12,13). Despite serum 
vitamin D levels correlating with disease activity in MS, supplementation has not shown any 
therapeutic effect when disease is manifest or in preventing conversion to clinically definitive 
MS (14–16). Furthermore, increased relapse rates have been observed during the darker winter 
months (17), which correlates to generally increased levels of melatonin, the secretion of which 
is in part inhibited by retinal exposure to blue light. Melatonin levels in have been shown to be 
negatively correlated with MS relapses in humans and mediate the severity of experimental 
autoimmune encephalomyelitis (EAE), an animal model of MS (18). Migration studies have 
also shed light on the importance of geographical location at different developmental stages. 
Migrating from a country with low incidence to one with high incidence during adolescence 
increases the risk of MS to levels comparable with that of the residential population (19). Fur-
ther environmental risk factors for MS include Epstein-Barr virus (EBV) infection, exposure 
to tobacco smoke and organic solvents, night-shift work and obesity in adolescence whereas 
seropositivity for CMV infection, use of oral tobacco, alcohol consumption and high coffee 
consumption have been associated with a lower risk of disease development (20–24). Diet has 
long been speculated to be a contributing factor in MS development, however, aside from a 
possible benefit of vitamin D supplementation, no conclusive contributory role has been found 
(25). The risk of developing MS attributed to genetic factors has been reduced compared to 
earlier estimates, with a 17% concordance rate between monozygotic twins according to recent 
studies (26). Genome wide association studies have identified over 200 risk loci underlying the 
predisposition for developing MS, most of which are associated with regulation of the immune 
system (27,28). The most well-characterized associated allele is the human leukocyte antigen 
(HLA) class II DRB1*15:01, encoding the major histocompatibility complex II (MHC II), 
which confers a three times increased risk for development of MS. The HLA class I allele 
A*2:01, on the other hand, is protective against MS. When combining known genetic and en-
vironmental risk factors, the risk of developing MS increases notably, indicating a significant 
gene-environment interaction (23).  
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3 MS PATHOLOGY 
The immune system is developmentally conditioned to protect against disease. Immune system 
recognition and interaction with host cells, autoimmunity, is an important part of this function. 
Autoimmune disease defined as the result of aberrant immune interactions, which has been 
shown in several aspects of MS pathology.  
3.1 ADAPTIVE IMMUNE SYSTEM IN MS 
The adaptive immune system is responsible for elimination of pathogens with high specificity 
through several adaptable mechanisms. What distinguishes the cell lineages of the adaptive 
immune system is the development of highly specific receptors that can target a wide range of 
antigens through a process called V(D)J recombination which allows a great number of possi-
ble receptor genes through rearrangement of sets of receptor gene segments. The two major 
cell types of the adaptive immune system are T cells and B cells, each with distinct functions. 
Both of these lymphocyte subsets can be further divided based on functionality and surface 
markers such as cluster of differentiation (CD). CD4+ T cells and CD8+ T cells have been cen-
tral to the current understanding of MS pathology and will be further elaborated upon below. 
3.1.1 T cells 
CD4+ T cells, also known as T helper cells (Th cells), are instrumental in orchestrating a range 
of immune responses. Derived from hematopoietic precursors in the bone marrow, T cells de-
velop and mature through a series of positive and negative selection based on their T cell 
receptor affinity and specificity in the thymus. CD4+ T cells are activated by receptor binding 
to peptides presented on MHC class II by antigen presenting cells (APCs) and can then differ-
entiate into different CD4+ T cell subsets including Th1, Th2, Th17 and T regulatory (Treg) cells 
depending on composition of co-stimulatory molecules. When activated, CD4+ T cells support 
effector cells such as macrophages and CD8+ T cells, which in turn are responsible for phago-
cytosis and clearing of cellular debris as well as cell mediated cytotoxicity. Adoptive transfer 
of myelin specific CD4+ T cells in rodents is sufficient to result in EAE. Supported by this 
causal role in EAE, CD4+ T cells have long been seen as a key component in MS pathogenesis. 
Treg cells, a subset of CD4+ T cells expressing CD4, forkhead box P3 and CD25 are driven by 
transforming growth factor (TGF)-β signaling, are considered important in suppressing inflam-
mation and self-reactivity in MS (29). 
CD8+ T cells are important for defense against intracellular infections and elimination of dam-
aged cells. Their primary effector functions are release of cytotoxins such as granzymes, and 
perforins that induce cell death. They also secrete the proinflammatory cytokines tumor necro-
sis factor alpha (TNF-α) and interferon gamma (IFN-γ). Intrathecal levels of CD8+ T cells are 
correlated with myelin destruction axonal degeneration in MS lesions (30). Subsets of CD8+ T 
cells include central memory and effector memory T cells (Tcm and Tem, respectively), which 
retain cytotoxic capabilities and are thought to provide protection against chronic infections 
(Tcm) and certain viruses and bacteria (Tem) (31). 
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3.1.2 B cells 
Since the clinical efficacy of B cell-depleting therapies such as RTX and ocrelizumab has be-
come evident (see Paper I), interest in the immunopathological role of B cells in MS has risen 
sharply and altered its emphasis. The antibody production of plasma B cells has historically 
been of much interest due to their increased production of a narrow set of immunoglobulins 
(Ig), termed oligoclonal bands (OCB), and are highly correlated with elevated IgG levels in-
trathecally (32). Although OCBs occurs in other diseases, such as neuromyelitis optica, 
neurosarcoidosis, syphilis and multiple myeloma, as mentioned earlier, it is included as a cri-
terium for an MS diagnosis. Defining common CNS targets of these Igs between patients has 
with current efforts been elusive as they are usually specific to ubiquitously occurring autoan-
tigens. Further, immunoglobulin reactivity to myelin oligodendrocyte glycoprotein and other 
plausible CNS specific molecules does not differ significantly between MS patients and con-
trols (33). Focus has thus shifted to the pathogenic influence of the B cells’ cytokine release 
and role as an APC (34). B cells has recently been found to interact with T cells in a HLA-DR-
dependent manner to support autoproliferation of T cells likely to target an autoantigen present 
in brain parenchyma (35). Clinically, the MS biomarker chemokine (C-X-X motif) lig-
and(CXCL)13 functions as a chemoattractant for B cells and CSF levels correlate both with 
markers of disease activity and can be used to predict treatment response (36,37).  
3.2 INNATE IMMUNE SYSTEM IN MS 
The innate immune system constitutes the first line of defense against various pathogens, car-
rying fixed and unadaptable repertoires of receptors named pattern recognition receptors. 
Recognition of antigens by these receptors lead to a release of several proinflammatory proteins 
such as cytokines interleukin (IL)-1, TNF-α and IFN-γ, collectively inducing the classic signs 
of inflammation. The innate and adaptive immune system cooperates through cytokine signal-
ing, antigen presentation on MHC class II molecules and, possibly, production of ROS. Of the 
many components of the innate immune system, monocytes and macrophages are the most 
relevant within the confines of this thesis. 
3.2.1 Monocytes and macrophages 
The main effector functions of monocytes and macrophages are antigen presentation, phago-
cytosis and cytokine production. Common cytokines produced by monocytes include IL-1, IL-
12 and TNF-α. In turn, IFN-γ, often secreted by CD4+ T cells, are necessary for macrophage 
activation and phagocytosis, whereas chemokine (C-C motif; CCL)2 and CCL7 are typical 
factors regulating monocyte homing. The surface markers CD14 and CD16 are often used to 
distinguish subpopulations of monocytes, from classical (CD14+CD16-) to non-classical 
(CD14+CD16++) and intermediate (CD14++CD16+) monocytes. Monocyte ROS production is 
hypothesized to be a regulatory factor in the interplay with CD4+ T cells, as impaired ROS 
production has been associated with chronic inflammation (38).   
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3.3 PATHOLOGICAL CHARACTERISTICS OF MS 
Characteristic pathological features of MS encompass demyelination in both white and grey 
matter, axonal degeneration, reactive gliosis and increased vascular permeability at lesion sites 
in the described typical locations. In active MS lesions, there is perivascular and parenchymal 
infiltration of macrophages (histologically described as a sea of macrophages), T cells (CD8+ 
and CD4+), B cells and plasma cells in decreasing order. Resident astrocytes swell up and form 
multinucleated hypertrophic gemistocytes (39) creating a matrix in which the other cells are 
suspended. Oligodendrocytes, responsible for the neuronal myelin sheaths are usually damaged 
in various degrees, but also show signs of active remyelination (40). Ig depositions and com-
plement activation is often present, which in conjunction with the previously described give 
rise to a heterogenic pattern of lesions that can be categorized into distinct categories which 
vary between patients (41). ROS production by infiltrating macrophages and resident microglia 
contribute to myelin damage, though much point towards ROS also being necessary for regu-
lation of inflammation through CD4+ T cell signaling (38,42). Several hypotheses have been 
proposed regarding the precipitating event in MS and can roughly be divided based on whether 
it is thought to be initiated peripherally or in the central nervous system (CNS). Molecular 
mimicry, epitope spreading and bystander activation are some of the hypotheses that have been 
proposed as an “outside-in” mechanism (43–45). Activated by the recognition of a self-antigen, 
CD4+ T cells are thought to differentiate peripherally to Th1 and Th17 cells, cross the blood-
brain barrier (BBB) and propagate an autoimmune reaction through recruitment of monocytes 
and further activation of CD4+ T cells and local microglia (46). In the “inside-out” model, the 
autoimmune response is considered secondary to a degenerative process within the CNS. Neu-
roaxonal degeneration has been shown to occur already in early stages of MS and is not 
dependent on neuronal demyelination (47). 
In SPMS, meningeal ectopic germinal centers, containing follicular dendritic cells, B cells and 
plasma cells, have been described, which might secrete soluble factors driving cortical demy-
elination (46). Wide-spread activation of resident microglia has also been observed, capable of 
further driving the disease process through secretion of ROS, complement factors and inflam-
matory cytokines (48).  
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4 CLINICAL ASPECTS OF MS 
4.1 MS SYMPTOMS 
MS patients experience symptoms across many different functional systems depending on the 
locations new lesions appear. Initial symptoms often include vision disturbances, sensory ab-
normalities such as numbness or paresthesia and muscle spasms or weakness which is 
complicated by difficulties with balance and coordination and musculoskeletal pain leading to 
impairments in mobility. With time, many patients often also experience cognitive and speech 
deficits, mood disorders and bladder and bowel problems. Fatigue is one of the most common 
symptoms in MS, occurring in up to 90% of patients (49). While there’s no set definition of 
fatigue, most patients describe it as a “reversible motor and cognitive impairment, with reduced 
motivation and desire to rest” (50), and about 40% of patients find it is their most debilitating 
symptom. Fatigue correlates with depression, low quality of life, reduced activities of daily life 
and physical activity with a likely bidirectional influence (51,52). 
4.2 MS DIAGNOSIS 
Clinically, RRMS is diagnosed by assessing relapses, which are acute focal neurological defi-
cits associated with immune-mediated demyelination lasting at least 24 hours and with varying 
rates of functional recovery (53). MRI has not only had a profound effect on the understanding 
of the development of MS pathology over time, it has also become a main pillar in the diagnosis 
of MS, showing evidence of ongoing and past demyelination events as well as regional and 
general atrophy. It should be noted, however, that MS can be diagnosed without the use of an 
MRI. The diagnosis of MS is based on evidence of disease activity being dispersed in time and 
space (54). This means a patient must display symptoms of at least two lesions in the CNS 
occurring at separate occasions. Typical regions of the CNS that are affected are divided into 
cortical or juxtacortical, periventricular, infratentorial and spinal cord. The MRI diagnostic cri-
teria from the recent MAGNIMS guidelines support optic neuritis counting as a separate lesion 
and allows presence of OCB in CSF to substitute for time dispersion of lesions in patients with 
clinically isolated syndrome (CIS) (55). Patients are diagnosed with CIS based on clinical evi-
dence of a single relapse suggestive of MS. Presence of MRI lesions in these patients increase 
the risk of being diagnosed with MS from 20 to 90% (56). Treatment of CIS patients with 
DMTs also lowers the risk of further demyelinating events and conversion to definite MS 
(57,58). Patients incidentally presenting with MRI lesions suggestive of MS and no neurolog-
ical manifestations are diagnosed with Radiologically isolated syndrome (RIS), of which 34% 
convert to MS over a 5-year period (59,60). The diagnosis of PPMS relies mainly on clinical 
parameters of disease accumulation, though also supported by the occurrence of OCB in the 
CSF and MRI lesions. PPMS and SPMS is often further divided into active and/or progressive 
depending on occurrence of relapses, MRI activity and progressive accumulation of functional 
deficits (61). Differential diagnoses that should be ruled out before MS is diagnosed include 
neuromyelitis optica, neurosarcoidosis, Lyme disease, acute demyelinating encephalomyelitis, 
cerebral vasculitis, Arnold-Chiari malformation, systemic lupus erythematosus and Sjögren’s 
disease (62). 
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4.3 MS BIOMARKERS 
Complementary to the clinical assessment and MRI, there are several biomarkers that reflect 
the disease processes of MS that are currently being evaluated for clinical usefulness. The bi-
omarker garnering most attention in later years has been neurofilament light (NFL). NFL is an 
integral part of the axonal structure and is exuded into CSF and blood upon neuronal injury, 
which include inflammatory, degenerative and traumatic causes. In MS, CSF and serum NFL 
increases with both clinical relapses and Gd+ MRI lesions, and correlates moderately with the 
clinical severity scale Kurtzke Expanded Disease Severity Score (EDSS), explained in greater 
detail in the next section (63–65). As a prognostic marker, high NFL levels correlates increased 
accumulation of disability and earlier conversion to SPMS (66). Other biomarkers include ma-
trix metalloprotein (MMP)-9 in CSF and serum which correlated with disease activity and also 
distinguishes MS from other inflammatory neurological diseases (67). Osteopontin, a phospho-
protein found in extracellular matrix that interacts with several types of integrin receptors, 
correlate with MS disease and increase with disease activity (68). OCB, IgG-index and 
CXCL13 are biomarkers further discussed in sections 3.13 and 5.2. 
4.4 MS FUNCTIONING SCALES 
Several scales for measuring the clinical severity of MS have been proposed and are used to 
varying degrees between countries and clinics. The most widely recognized scale internation-
ally is EDSS (69) which assesses impairment in eight functional systems including visual, 
brainstem, pyramidal (motor), cerebellar (coordination), sensory, bladder/bowel and cerebral 
(cognition) components. The scale uses an ordinal rating system in 0.5 increments (after EDSS 
1) that ranges between 0 and 10, representing normal neurological status and death due to MS, 
respectively. Scores between 0 and 3.5 measures impairment in the defined functional systems, 
4.0 to 7.0 focusing on walking ability and walking aids, and 7.5 to 9.5 dependence on help. The 
scale is most often used to measure disease outcomes in clinical trials, usually secondary to 
relapses and MRI lesions. EDSS correlates moderately to MRI lesion load, though is heavily 
weighted towards corticospinal lesions as they usually result in greater functional impairments 
(70). Correlations are, however, strengthened when combined with measures of brain atrophy 
(71). 
4.5 MS COMORBIDITY 
Comorbidities are common among patients with MS and vary over time. Among newly diag-
nosed patients, chronic lung disease (4.9%), hypertension (3.8%), hypercholesterolemia 
(2.7%), depression (7.4%) and anxiety (2.7%) occur most frequently (72). Rates of past and 
current obesity are also higher among MS patients at diagnosis (73). Across all MS patients, 
depression (23.7%), anxiety (21.9%), hypertension (18.6%) and hyperlipidemia (10.9%) are 
among the most commonly occurring comorbidities, based on a systematic review including 
studies from Europe (52.2%) and North America (33.7%). Over time, the prevalence of hyper-
tension, diabetes, hyperlipidemia, ischemic heart disease and fibromyalgia tend to increase 
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(74). Occurrence of comorbidities have been associated with increased relapse rate, disease 
progression as well as earlier treatment discontinuation, often due to tolerance issues (74). 
5 MS TREATMENT 
The range of RRMS treatments has expanded rapidly and considerably since the introduction 
of interferons in 1993 (75). As of 2019, there were in total 18 approved DMTs for RRMS, 
which had undergone clinical testing using placebo or the oldest available DMTs as compara-
tors in mostly treatment naïve patients, underscoring the need for comparative prospective trials  
between reasonable treatment alternatives (76). As a result, treatment strategies have in the past 
years varied significantly both between and within countries. In many countries, including the 
US and those comprising Europe, the most common strategy remains an escalation type strat-
egy, starting with the oldest, least effective drugs (first line) and escalating to more efficient 
(second line) therapies when patients display signs of disease breakthrough. One of the main 
rationales for this being the lower risk of serious adverse events with the first line drugs such 
as interferons or glatiramer acetate (77,78). Replacing this strategy with using highly efficient 
therapies early on has been a topic of much discussion (79,80) and has in the past years been 
the prevailing strategy in most Swedish counties (see Paper I and II). Epidemiological findings 
seem to favor this strategy, showing relapse rate in the first two years influencing disease course 
and an increased time to disability milestones among patients with highly efficient therapies 
early in disease (81,82). A recent retrospective observational study which included patients 
from both the international MS registry, MSBase, and the Swedish MS registry, showed that 
patients treated with a highly efficient therapy within two years (in contrast to after four to six 
years) of clinical disease onset had significantly lower levels of disability at six and ten years 
follow-up (83). An induction type strategy, combining initial use of rituximab, a highly effec-
tive treatment, followed by subsequent continuous use of glatiramer acetate, a common first 
line therapy, showed lowered risk disease activity up to 30 months after treatment initiation 
compared to glatiramer acetate monotherapy (84). Included among highly efficient therapies 
are monoclonal antibodies rituximab, ocreluzumab (both targeting CD20), natalizumab (a4b1 
integrin) and alemtuzumab (CD52) along with mitoxantrone (a topoisomerase inhibitor). Not 
usually included when discussing highly effective treatments, but with corresponding or higher 
efficacy is autologous haemopoietic stem-cell transplantation, which in a phase II study showed 
up to 78-83% total absence of disease activity (85). Due to a comparatively high mortality rate 
(~5%), however, it usually reserved for patients with early aggressive disease activity refrac-
tory to highly effective treatment alternatives. 
5.1 DIMETHYL FUMARATE 
Initially developed as a treatment for psoriasis, DMF was by chance found to be effective also 
for RRMS patients and was approved for that indication in 2013 (86). Through the DEFINE 
and CONFIRM trials and their extension trial ENDORSE, DMF displayed a moderate effi-
ciency for decreasing relapse rates and gadolineum contrast enhancing (Gd+) and newly 
appearing T2 lesions and has since become the most prescribed RRMS drug in the US (87–
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89). Early studies in EAE showed that DMF binds irreversibly to Kelsh-like ECH-associated 
protein 1 (Keap1), thereby increasing the activity of Nrf2, a central transcription factor for 
several antioxidative and cytoprotective enzymes, such as NADP(H) quinoline oxidoreductase-
1 (NQO1) (90). Notably, Nrf2 activation is well described as a consequence of physical exer-
cise (91). Despite these findings, evidence of CNS penetration in humans has not been shown, 
leading to speculation that it primarily exerts its effects through peripheral immunomodulation 
(92). DMF exerts a direct modulatory effect on microglia through activation of the hydroxycar-
bolic acid receptor 2 (HCAR2) resulting in inhibition of NF-kB and lower secretion of pro-
inflammatory cytokines (93,94). As shown in Paper III, DMF treatment dependent increases in 
circulating monocytes and monocytic ROS production predict treatment response among pa-
tients (95). Insufficient treatment response was also correlated with the minor G allele of the 
NADPH oxidase (NOX)3 gene involved in ROS generation. DMF also affect circulating con-
centrations of leucocytes, reducing CD8+ and CD4+ T cells and subsets of central memory 
(CD45RA- CCR7+) and effector memory (CD45RA- CCR7-) T cells, Tc17 cells (IL-17 secret-
ing CD8+ T cells), CD56dim natural killer (NK) cells, CD19+ B cells and plasmacytoid dendritic 
cells, while increasing naïve (CD45RA+ CCR7+) T cells and leaving Treg cells unchanged 
(figure 2; 96–98). How this is regulated is unclear, though studies have shown DMF to induce 
apoptosis in active subsets of T cells (99). Through inhibition of glyceraldehyde 3-phosphate 
dehydrogenase (GADPH) and in extension aerobic glycolysis in activated immune cells, DMF 
promotes development of Treg cells while inhibiting differentiation and proliferation of Th1 and 
Th17 cells (100). Human studies show low levels of DMF in circulating plasma after intake, 
whereas intracellular GSH levels rapidly decrease (101). Rapid depletion of intracellular glu-
tathione (GSH) levels is hypothesized to generate an anti-inflammatory cytokine response or 
cell apoptosis. Decreased levels of GSH in T cells have been correlated with downregulation 
of Th1 cytokines (102) supported by CD4+ T cell production of IFN-γ and IL-17 having been 
found to decrease with DMF treatment whereas IL-4 production increases (97). DMF exerts a 
wider range of effects than those studied within this thesis, as reviewed by Yadav et al. (103). 
Clinically, adverse events such as flushing (believed to be HCAR2-mediated) and gastrointes-
tinal upset are among the most common causes of discontinued use (see Paper I & II) (104). 
There have been case reports of patients suffering progressive multifocal leukoencephalopathy 
(PML) in association with DMF treatment, all cases with associated lymphocytopenia (105). 
Also seen among patients treated with natalizumab, PML is a disease caused by an opportun-
istic viral infection of the John Cunningham virus (JCV) which is present in approximately 40 
to 60% of the population (106). One case has been reported with Listeria Monocytogenes-in-
duced rhombencephalitis, a foodborne usually severe intracellular infection, with the patient 
having a slight reduction in lymphocyte count (107).  
5.2 RITUXIMAB 
Initially developed as a therapy for patients with non-Hodgkin’s lymphoma, RTX has since 
gained an important role in the treatment of several diseases within hematology, rheumatology 
and neurology. The list of diseases under investigation for a therapeutic effect by RTX is still 
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increasing. Within clinical neurology, it has become widely used for neuroinflammatory dis-
eases with off-label use for diagnoses including neuromyelitis optica, myasthenia gravis, N-
methyl-D-aspartate receptor encephalitis and other autoimmune encephalitides (108–110). 
Pharmacodynamically, RTX is a chimeric monoclonal antibody against CD20 which is pri-
marily expressed on B cells. In Paper I, we showed that RTX is a highly effective and safe 
treatment for RRMS. Other, further humanized CD20 antibody treatments have also been ap-
proved for clinical use and include ocrelizumab (90-95% humanized) and ofatumumab (fully 
humanized), the former with partially overlapping epitope and clinical efficacy in RRMS pa-
tients comparable to that of rituximab as shown in the OPERA I and II trials (111). RTX 
treatment leads to the lysis of CD20+ B cells through antibody-dependent cellular cytotoxicity 
(mediated by carriers of Fcγ receptors such as monocytes, neutrophils and NK cells), comple-
ment-dependent cytotoxicity and apoptosis (112). CD20 is present on later stage developing B 
cells to mature and memory B cells, the latter a reservoir for EBV, a known risk factor for MS 
(113). Antibody producing plasma B cells, however, do not express CD20, and CSF OCBs 
remain despite therapeutic effect, leading to an exploration of antibody independent B cell con-
tributions to MS disease (see section 3.1.2). CD20 has also been found in subpopulations of T 
cells, sparking debate on the main mode of action for anti-CD20 antibodies in autoimmune 
inflammatory diseases (114). The repopulating naïve B cells following RTX treatment secrete 
less proinflammatory cytokines (IL-6, TNF-α and granulocyte-macrophage colony-stimulating 
factor), and higher levels of IL-10 that mediates an anti-inflammatory effect on T and myeloid 
cells (115). RTX treatment has been associated with an increased susceptibility to serious in-
fections compared to both moderate and highly effective treatment alternatives (116). Although 
cases of PML have been reported among RTX treated patients with other inflammatory and 
non-inflammatory diseases, occurrence is rare (117,118).  
Figure 2. Schematic summary of the reviewed mechanisms for DMF. Dimethyl fumarate exerts a wide range of 
effects on immune cells and neurons. Changes in levels of T cell subsets such as T effector memory (Tem) and T 
central memory (Tcm) cells have been extensively described, although several other cell types are affected. 
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6 EXERCISE AND MS 
The clinical approach to physical exercise for patients with MS has changed profoundly during 
the past century. Early on, absence of even moderately demanding physical activity was 
deemed critical for MS patients to avoid further neurological deterioration (119). This recom-
mendation was influenced by the tendency of MS symptoms temporarily worsening with 
increased body temperature, typically brought on by heat exposure or physical exertion, known 
by its clinical term as Uhthoff’s phenomenon. In 1963, however, a report by Geisler et al. (120) 
provided proof of successful outcomes from exercise related rehabilitation and research interest 
has been steadily increasing since. Accumulating evidence shows benefits of physical exercise 
along several functional domains for MS patients (reviewed in (121)). Despite this, MS patients 
are less likely to exercise (122) and participate in social/lifestyle activities (123), likely in part 
due to the high prevalence of fatigue along with motor and coordination deficits (51). Com-
pared to healthy controls, MS patients across all subgroups are in poorer physical condition 
regarding aerobic capacity, maximal muscle strength, gait velocity and health-related quality 
of life (124). Areas of less well-established disease impact include increased resting heart rate, 
increased diastolic blood pressure, increased muscle atrophy, decreased muscle mass, de-
creased fat-free mass, and shifts in muscle fiber type (124). While DMTs reduce disease 
activity and disease progression, exercise remains the only way to improve function in MS, at 
least in the long term (82,125). Exercise can be classified into different types depending on the 
type of muscle contraction, intensity and duration. For the purposes of distinguishing exercise 
protocols for MS patients, the most commonly used are aerobic (endurance), strength, balance 
and stretching exercises. Exercise is also commonly grouped with other activities, such as re-
habilitative exercises (strength and endurance exercise in combination with stretching, 
psychotherapy etc.) and occupational therapy (work-oriented activities and exercises) and is 
generally regarded as safe for MS patients (126). Recommendations regarding type, frequency 
and duration of exercise has been formulated in the Canadian Physical Activity Guidelines for 
Adults With Multiple Sclerosis (127). The guidelines are based on a systematic review of ex-
ercise literature and a consensus meeting with stakeholder involvement. As the impact of 
exercise on clinical parameters is becoming better understood, one of the current main chal-
lenges of the field is to optimize exercise protocols for specific functional deficits, as well as 
to understand the molecular basis of how the beneficial effects are mediated.  
6.1 EXERCISE EFFECTS ON MS SYMPTOMS AND COMORBIDITY 
Increasing evidence support the beneficial effects of exercise on ameliorating MS symptoms, 
with varying efficiency depending on exercise type. Benefited areas of function involve walk-
ing mobility, balance, cognition, fatigue, depressive symptoms and health related quality of life 
(128–131). Also, comorbidities commonly associated with MS (described prior) benefit sig-
nificantly from exercise (132).  
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6.2 EXERCISE EFFECTS ON MS IMMUNOLOGY 
Aside from the ameliorating effects on many symptoms, accumulating evidence shows that 
exercise also likely has a modulating effect on inflammation in MS (133,134). Epidemiological 
studies partially support the notion of a protective effect of exercise on MS incidence (135,136) 
and disease burden (137). A systematic review of relapses in exercise studies found a 27% 
decrease of relapses in exercise intervention groups compared to controls, whereas retrospec-
tive epidemiological studies have not shown a correlation (138,139). Premorbid activity levels 
and peak aerobic capacity predict disease progression in MS, though resistance exercise did 
not ameliorate rate of brain atrophy or decrease lesion load despite increasing cortical thickness 
and functional scores (140–142). Although long-term effects of exercise in MS patients have 
not been studied, reductions in disability accumulation and neuronal loss are assumed based on 
current experimental findings, represented schematically in figure 3 (143). However, exercise 
has not been found to influence peripheral levels of T cells, B cells, NK cells or monocytes in 
patients with IFN-b treatment (144). 
 
 
Figure 3. Hypothesized long-term clinical effects of exercise added to standard MS therapy. The normal course of disease 
progression is marked in grey bars, with a corresponding exercised disease course overlaid in green bars. Observed benefits of 
exercising MS patients include lower relapse rate (as shown by the green bars) and, speculatively based on EAE findings, 
slower accumulation of disabilities. 
 
6.2.1 Immunomodulatory effects of exercise in EAE 
Much of the current understanding of the immunological aspects of MS has been derived from 
animal models, predominantly from rodents. Of the experimental models of MS, EAE is the 
most commonly used. Though there are significant discrepancies between the disease course 
and lesion distribution and disease driving cell subsets, the pattern of demyelination and axonal 
damage is highly similar (145,146). Studies on EAE have shown that intense, but not moderate, 
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exercise can delay the onset of disease, time to maximum disease severity and decrease dura-
tion of disease exacerbation (147–149). It did not, however, have an influence on maximal 
disease severity (147,150). Timing has been shown crucial for the immunomodulatory effects 
of exercise. Exercise prior to disease induction had no influence on the disease course, whereas 
exercise after induction delayed disease onset (150). Since exercise interventions are initiated 
after diagnosis, i.e. after the patient has incurred a neurological deficit, Motl et al. initiated their 
exercise intervention at the remission of the first relapse. In this setting, exercise had no influ-
ence on disability scores or hippocampal brain-derived neurotrophic factor (BDNF) (151). 
Adoptive transfer of T cells from intensely exercised EAE mice resulted in a milder disease 
course in recipients. The same T cells proliferate in lower rates and had lower production of 
TNF-α, IFN-γ, IL-17 and IL-10 after exposure to myelin components in vitro (148). Lower 
levels of IFN-γ, IL-17 and IL-1β in spinal cord was also found after exercise (149).  
6.2.2 Exercise and cytokines in MS 
Cytokines are short peptides with various cell-signaling functions, importantly including im-
mune modulation. Several cytokines have been of interest in MS due to findings either from 
clinical samples or studies of EAE. TNF-α was thought to be an important promoter of MS 
given that levels were increased in the CSF of patients and were correlated with disease pro-
gression and blockade in EAE resulted in significant reduction in disease severity (152,153). 
Unfortunately, clinical trials saw an increase in disease activity among patients receiving anti 
TNF-α antibody treatment (154). CXCL13 is important for B cell homing to CNS and levels 
are predictive of disease exacerbations and prognosis (155). Several other cytokines have been 
detected among MS patients, including IL-6, CCL4, CCL22, CXCL10 (156,157), but incon-
sistencies across studies remain problematic. This also pertains to cytokines associated with 
exercise interventions in MS (133). Cytokines TNF-α, IL-6 and IL-10, which have been impli-
cated in MS all show inconsistent changes in peripheral concentrations (158–161). 
6.2.3 Exercise and neurotrophic factors in MS 
Neurotrophic factors are important mediators for cell survival and synaptic plasticity and have 
been associated with both exercise and MS pathology (162). Increased levels of nerve growth 
factor receptors have been found in active MS lesions and on microglia/macrophages (163). 
Brain-derived neurotrophic factor (BDNF) is increased in the relapse and recovery phase of 
RRMS and is decreased in SPMS. Basal levels of serum nerve growth factor are increased in 
MS patients and are further increased after acute aerobic exercise compared to healthy controls. 
BDNF concentrations increased with exercise but not more so than for controls in the same 
study (164), but this is inconsistent across studies (133,144,165) 
6.2.4 Exercise in combination with DMF for treatment of MS 
An interesting finding in EAE showed that DMF in combination with exercise was associated 
with a greater clinical improvement and increased preservation of synaptic motor neuron input 
density in comparison to DMF alone or a comparator drug combined with exercise, indicating 
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a positive exercise DMT interaction (166). Corresponding studies on MS are yet to be con-
ducted, although some existing studies have controlled for on-going DMT (e.g. see 
Kierkegaard et al. (158)). Whether the mode of action of exercise and DMF are complementary 
or overlapping has not been explored and was indirectly the subject of investigation in Paper 
IV. Prior studies have shown that both therapy modalities potentially mediate neuroprotective 
and immunomodulatory effects through redox signaling and activation of Nrf2 (90,95,167). 
Exercise also increases levels of D-β-hydroxybuturic acid, a ketone body synthesized from 
acetoacetate, which binds to the G-protein-coupled receptor HCAR2 common to DMF. In 
EAE, HCAR2 activation through DMF has been shown to reduce neurological deficits by de-
creasing neutrophil infiltration to the CNS and inhibition of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) in microglia, decreasing secretion of proinflammatory 
cytokines (93,94). Modulation of HIF-1a activity is also a common denominator for DMF and 
exercise although its regulation is dependent on exercise intensity and duration (95,168).  
6.2.5 Exercise effects on healthy participants 
The benefits of exercise for healthy participants have been extensively documented. The ben-
efits span a wide range of functional systems, including neurological, cardiovascular and 
endocrinological. Regular exercise and physical activity decreases all-cause mortality within 
the observation period in a dose-response manner, which has been shown in multiple large-
scale epidemiological studies (169–171). Immunologically, acute exercise bouts of less than 
60 minutes increase circulating levels of neutrophils, CD8+ T cells, NK cells and naïve B cells 
(172), thought to participate in a temporarily increased immune surveillance. Most commonly 
upregulated cytokines in association with exercise are IL-4, IL-6, IL-8, IL-10 and IL-12p40 
(173). IL-6 is released directly from muscle tissue and participates in regulating inflammation 
through release of cortisol and blunting the TNF-α response. Exercise also gives rise to the 
release of other related proteins such as fibroblast growth factor (FGF)21 which regulates in-
sulin sensitivity and glucose metabolism among several other functions (174).  
6.2.6 Exercise and the kynurenine pathway 
A potential exercise related marker for immunomodulation is the tryptophan metabolite 
kynurenic acid (KYNA) which is neuroprotective against excitotoxicity (175). Agudelo et al. 
have shown that exercise induces skeletal muscle peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α) which through increased expression of kynurenine ami-
notransferases enhances the conversion of kynurenine to KYNA (176). This shift resulted in a 
protection from stress-induced changes associated with depression. Kynurenine and 3-hy-
droxykynurenine are also involved in glutamate metabolism and neuroinflammaton. Exercise 
has been shown to increase KYNA peripherally also in humans, though no studies have been 
conducted on MS patients (177).  
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7 THESIS AIMS 
 
The overarching aim of the thesis was to determine the clinical effects of the MS drug DMF, 
explore its mode of action and compare it to that of physical exercise to identify possible com-
mon denominators. 
 
Paper I 
To evaluate the clinical effectiveness of DMF in comparison to other initial treatment options 
for patients with RRMS in Stockholm and Västerbotten counties and assess frequency and 
severity of adverse events.  
Paper II 
To evaluate clinical effectiveness of DMF in comparison to common initial and secondary 
treatment options for patients with RRMS with nationwide coverage and assess frequency and 
severity of adverse events.  
Paper III 
To characterize the effect of DMF on RRMS patient lymphocyte and monocyte counts, func-
tion and inflammatory mediators to distinguish patients responding to treatment with absence 
of clinical disease activity from non-responders.  
Paper IV 
To characterize the effect of aerobic exercise on inflammatory protein markers in plasma and 
CSF on healthy human participants. 
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8 METHODS 
8.1 THE SWEDISH MS REGISTRY 
The Swedish MS registry was launched in 2001 as part of the Swedish neuro registries that 
collects data on several neurological diseases including myasthenia gravis, Parkinson’s disease 
and epilepsy. To date, the registry includes 20571 patients from all 21 counties in Sweden with 
a coverage rate almost 80% of prevalent MS cases (178). The data collected include patient 
characteristics, clinic visits, measures of clinical disease activity such as relapses and MRI le-
sions, therapies, functional scales, laboratory tests and are registered through an internet-based 
platform by physicians and nurses. The registry has served as the basis for more than 100 sci-
entific reports spanning from epidemiological to neuroimmunological and genetic studies 
(178). A recent validation study from our group showed high validity for registered data (179). 
The registry was the primary data source for Paper II and was an important source for cross-
referencing medical record data in Paper I. 
8.2 THE KAPLAN-MEIER ESTIMATOR 
The Kaplan-Meier estimator is a widely used univariate analysis that describe survival based 
on one predictive factor. In a clinical setting, these events are typically clinical signs of disease 
progression, discontinued treatment use or disease related death. Kaplan-Meier curves are fre-
quently used to visualize these probabilities over a given time period (as in Paper I & II). 
Kaplan-Meier estimators are usually a univariate model, which means confounding factors 
such as age, sex and comorbidities are not adjusted for, which should be taken into account 
when interpreting results. 
8.3 COX PROPORTIONAL HAZARDS REGRESSION 
The Cox proportional hazards regression is the most common method for assessing the influ-
ence of predictor variables on survival rates in clinical studies. As with Kaplan-Meier 
estimations, it is often used for risk of treatment discontinuation (as in Paper I & II) and disease 
progression on treatment but can factor in multiple independent (predictor) variables to the 
outcomes. The model is based on the assumption that the effects of the predictor variables on 
an event are constant throughout the observation period and provides unreliable results when 
these conditions are not met. 
8.4 PROPENSITY SCORE 
The propensity score is a commonly used method in observational treatment studies with two 
or more treatment options. In absence of randomization to treatment, patients are often more 
likely to be assigned a certain treatment depending on a set of observed covariates, collectively 
termed confounding factors. The propensity score is utilized to factor in this in the assessment 
of study outcomes and is formulated as a probability ranging between 0 and 1. The propensity 
score can be used in several ways to control for confounding on effect size of treatment, such 
as propensity score matching and covariate adjustment using the propensity score. The latter is 
used in Paper I as an add on factor in hazard rate calculations on drug survival and clinical drug 
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efficacy measures. The benefits of the propensity score are limited by available clinical char-
acteristics, favoring larger sets of variables (180). 
8.5 PROXIMITY EXTENSION ASSAY 
The proximity extension assay (PEA) uses a proximity extension technology to enable a high 
throughput multiplex proteomic immunoassay (181). The panel included in Paper III and IV 
contained 92 cytokines and chemokines and a selection of other immune-related proteins. The 
assay utilizes epitope-specific binding and hybridization of a set of paired antibodies linked to 
oligonucleotide probes, which subsequently can be amplified using a quantitative polymerase 
chain reaction to quantify relative protein concentrations. The method thus allows for both 
highly specific protein detection with small quantities of sample. Due to limited use, docu-
mented methodological shortcomings relative to other proteomic approaches are sparse (182).  
9 RESULTS AND DISCUSSION 
9.1 PAPER I  
In this study, we conducted a retrospective observational cohort study on RRMS patients start-
ing initial treatment in two Swedish counties: Stockholm and Västerbotten. RRMS patients in 
Stockholm County treated with DMF had similar rates of drug discontinuation as did interfer-
ons, fingolimod and natalizumab. While the main focus of the article came to be rituximab due 
to its superior effect on both decreasing relapse rate (hazard rate adjusted for propensity score 
(HR) for discontinuing DMF in comparison to RTX was 15.1 (95% confidence interval (CI) 
3.9 – 58.0; see figure 4). Patients treated with DMF had a HR of 3.4 (95% CI 1.0 – 11.8) of 
having a relapse, HR of 8.4 (95% CI 1.7 – 72.1) of showing Gd+ on MRI and roughly double 
the rate of adverse events (50% for DMF compared to 23.3% for RTX) during the study period 
which spanned little over three years.  
 
 
Figure 4. Kaplan-Meier curve of drug discontinuation of RRMS patients in Stockholm and Västerbotten counties. Pa-
tients treated with rituximab (RTX) had significantly lower rates of drug discontinuation compared to alternatives. Dimethyl 
fumarate (DMF), on the other hand, proved comparable to interferons and glatiramer acetate (INJ jointly), which is standard 
initial therapy for RRMS in many countries. 
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We next compared outcomes of RRMS patients treated in Stockholm and Västerbotten due to 
the then strikingly different treatment strategies applied in the two counties. In Stockholm, most 
patients were initially treated with common treatment choices for newly diagnosed RRMS, 
including interferons, glatiramer acetate and, in increasing rates, DMF. In Västerbotten County, 
however, the same category of patients was consistently initiated on treatment with RTX, thus 
allowing for a natural experiment comparing treatment strategies. Drug discontinuation, rate of 
clinical relapses, Gd+ MRI scans and adverse events were for all newly diagnosed patients in 
Västerbotten County similar to that of patients treated with RTX irrespective of county of res-
idence, thereby partially mitigating potential selection bias with regards to selection of therapy 
(see figure 5). 
 
Figure 5. Kaplan-Meier curve of drug discontinuation of RRMS patients compared between Stockholm and Västerbot-
ten counties irrespective of specific treatment. The treatment strategy in Västerbotten County consistently favored rituximab 
treatment for newly diagnosed RRMS patients, whereas Stockholm County generally used standard options interferons and 
glatiramer acetate. Drug persistence was superior in Västerbotten County. 
 
The study provides class IV evidence for DMF being a safe and moderately effective initial 
therapy for RRMS patients. We identified several limiting factors, aside from the non-random-
ized study design that should be taken into consideration when interpreting results. Among 
others stated in the article were differing treatment follow-up guidelines, physician influence 
on therapy switching, lack of standardized procedures for registration of baseline data. Despite 
these shortcomings, similar outcomes for both RTX and DMF have been found in studies fol-
lowing Paper I. 
9.2 PAPER II 
While the comparative efficiency of DMF was assessed in comparison to RTX in Paper I, the 
clinical profile of DMF in comparison to interferons, glatiramer acetate and fingolimod was 
only partially investigated. This necessitated Paper II, where DMF was further characterized 
as both an initial and secondary treatment option in comparison standard choices for RRMS 
patients.  
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The second treatment cohort was collected retrospectively from the national internet-based MS 
registry (SMSreg; neuroreg.se), further described in the Methods section. As an initial treat-
ment for RRMS, DMF had a superior clinical effect to interferons and glatiramer acetate, the 
most common choices for newly diagnosed patients in an escalation treatment strategy (see 
section 5). The rate of drug discontinuation was lower among DMF treated patients (HR 0.46, 
95% CI 0.37 – 0.58; see figure 6), and had also a lower annual relapse rate (ARR; 0.04, 95% 
CI 0.03 – 0.06 compared to 0.10 95% CI 0.07 – 0.13) and time to first relapse was significantly 
longer (p < 0.05). As secondary therapy, DMF had a higher discontinuation rate than fin-
golimod (HR 1.51, CI 1.08 – 2.09, p < 0.05; see figure 7), but did not differ with regards to 
ARR (0.03, CI 0.02-0.05 vs 0.02, CI 0.01 – 0.04; p = 0.41) or time to first relapse (p = 0.20). 
 
 
Figure 6. Initial treatment of RRMS patients with either dimethyl fumarate (DMF) or interferons/glatiramer acetate 
(IFN/GA). Kaplan-Meier curve of drug survival on a nationwide cohort (a). Treatment continuation of DMF was superior to 
IFN/GA over three years. Causes of discontinuation for the specific therapies shown in b and c. The most common cause of 
drug discontinuation was adverse events among both IFN/GA and DMF treated patients. 
 
The most common cause of discontinuation for DMF as initial and secondary treatment was 
adverse events (17.2% and 20.8%, respectively) followed by disease breakthrough. Discontin-
uations due to unspecified reasons were high in both treatment groups including for comparator 
drugs. We speculated that this was in part driven by patients being placed on other more effec-
tive therapies such as rituximab. Assessing prescription rates for DMF and standard initial 
treatments interferons and glatiramer acetate, we found that they had decreased during the study 
period. Stratifying calendar year of prescription, however, did not influence discontinuation 
rates across the different therapies. In summary, Paper II suggests that DMF could benefit 
RRMS patients with a mild disease course as an initial therapy to a greater extent than interfer-
ons and glatiramer acetate. However, due to tolerability issues and the general shift towards 
early treatment with RTX in Sweden, clinical use of DMF is expected to remain limited with 
the current indication. 
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Figure 7. Secondary treatment of RRMS patients with either dimethyl fumarate (DMF) or fingolimod (FGL). Kaplan-
Meier curve of drug survival on a nationwide cohort. Treatment continuation of DMF was inferior to FGL over three years 
despite no differences in effects on clinical disease activity (a). Causes of discontinuation for the specific therapies shown in b 
and c. For FGL, the most common cause of drug discontinuation was adverse events, as was the case for DMF. 
 
9.3 PAPER III 
In parallel with establishing the clinical treatment effect on RRMS patients in Paper I & II, our 
research group sought to characterize the underlying immunological mechanisms through 
which DMF exerts its effects in humans. Prior studies had shown DMF to confer an ameliorat-
ing effect in EAE rats by increasing the activity of the transcription factor Nrf2 which regulates 
the expression of several antioxidant proteins, thereby modulating the oxidative environment. 
Paper III thus focused on further exploring the effects of DMF on redox balance and redox 
signaling in the innate and adaptive immune system. Due to the low penetrance of DMF across 
the BBB, the main immunological effect was hypothesized to occur in blood, as part of the 
peripheral compartment. 
Patients treated with DMF had increased circulating levels of the oxidative marker isoprostane 
8.12-iso-iPF2α-VI at three- and six-months follow-up compared to baseline. As 8.12-iso-
iPF2α-VI is generated through non-enzymatic oxidation, its increase reflects general shift to a 
more oxidative environment. This was further confirmed by comparing the transcriptional lev-
els of differentially expressed mRNAs in CD14+ monocytes at baseline and six months, which 
showed an enrichment in upregulation of genes involved in oxidative stress response.  
To examine the mechanistic aspects of the DMF treatment effect, patients responding to treat-
ment with absence of clinical signs of disease activity during an observation period of up to 
two years were distinguished from non-responders. Among responders, we observed higher 
levels of monocytes in blood after three months therapy persisting to 12 months. Lymphocyte 
counts were also lower at 12 months compared to baseline for responders (see figure 8). Mon-
ocyte ROS production assessed using dihydrorhodamine-123 in in vitro stimulation was higher 
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among responders, although general spontaneous ROS production was generally lower among 
DMF treated RRMS patients compared to untreated. 
A SNP in NOX3 (minor G allele) displayed association with both lowered ROS generation in 
monocytes (0.057) and non-response to DMF treatment (p = 0.036), suggesting a possible di-
rect link. Additionally, several SNP within NOX-producing complexes were associated with 
DMF treatment. 
 
 
Figure 8. Monocyte and lymphocyte counts in blood along with monocyte ROS production. Monocyte counts increased 
in patients responding to DMF treatment with absence of clinical signs of MS disease activity at three, six and 12 months 
compared to non-responders(e). Lymphocyte counts decreased at 12 months among responders (f). Monocyte production of 
reactive oxygen species also increased among responders at three and six months (h). 
 
DNA methylation changes in CD14+ monocytes profiled with Illumina EPIC arrays were as-
sociated with regulation of apoptosis, metabolism and cell communication were observed at 
three months compared to baseline but had reverted back at six months. CD4+ T cells, on the 
other hand, displayed methylation changes mostly between three and six months. Differentially 
methylated regions were associated with cell proliferation, apoptosis, migration and differenti-
ation of Th17 and Treg cells. 
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DMF responders also had altered proportions and numbers of several subsets of CD4+ T cells 
at six months. Responders had proportional increases but lowered number of naïve (CD45RA+ 
CCR7+) T cells, decreased proportion and numbers of TCM (CD45RA- CCR7+) cells and de-
creased proportions of TEM (CD45RA- CCR7-) cells. 
Cytokine levels for responders were lower for IL-12B, IL-17C, CCL28 and CXCL9 at six 
months compared to baseline.  
Collectively, these findings provide further support for the concept of monocyte ROS signaling 
being necessary for autoimmune regulation through regulation of T cells. Especially interesting 
is the possible direct genetical link between ROS generating capacity of monocytes and treat-
ment response to DMF.  
 
9.4 PAPER IV 
Given the inconsistencies in prior studies with regard to cytokine/chemokine levels following 
exercise interventions, we opted to explore a wide array of immune protein markers with the 
multiplex assay Olink™ (further description in section 8.5). 
In Paper IV we showed that healthy participants completing an intense aerobic exercise proto-
col for four days had upregulation of several immune protein markers when comparing follow-
up and baseline samples from CSF and plasma. The effects from moderately intense aerobic 
exercise, which comprised the second group were less pronounced. See figure 9 for protein 
marker results. 
Figure 9. Inflammatory protein markers in cerebrospinal fluid (CSF) and plasma in healthy participants after highly 
or moderately intense aerobic exercise. Volcano plots summarize the mean difference and significance (P) from paired 
Student t-tests comparing baseline and follow-up levels of inflammation-related proteins after intervention with moderate 
(left) or high (middle) intensity exercise in CSF (first row), plasma (2nd row). Combined analyses with both intervention 
groups for determining correlation between proteins levels and intensity of exercise is shown (right). The red dashed line 
indicates an exploratory cutoff of p=0.05 and associations with P-false discovery rate <0.05 are highlighted in red.  
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Vascular endothelial growth factor (VEGF)-A and fibroblast growth factor (FGF)-21 were 
among the prior known exercise associated markers that increased post intervention. Surpris-
ingly, common inflammatory cytokines such as IL-1, IL-6, TNF-α and IFN-γ did not occur in 
detectable levels either at baseline or follow-up, which may relate to technical issues with the 
detection platform.  
Tryptophan metabolites were analyzed along with neurotransmitters glutamate, gamma-ami-
nobutyric acid and serine using an ultra-performance liquid chromatography-tandem mass 
spectrometry system and high-performance liquid chromatography with fluorescence detec-
tion. CSF levels of kynurenic acid, picolinic acid and 3-hydroxykynurenine increased in the 
highly intense exercise group. Plasma levels of tryptophan and kynurenine decreased, in all 
approximating prior experimental findings in mice by Agudelo et al. (176). Interestingly, tryp-
tophan metabolites and inflammatory protein markers showed correlation for many markers in 
both CSF and plasma, indicating a co-regulation of the two systems.  
The findings in Paper IV underscored that importance of exercise intensity as a determinant for 
regulation of inflammatory protein markers. Relating to EAE studies, higher intensity of exer-
cise also yields a greater inhibitory effect on disease severity, as seen in Fainstein et al. (148). 
High intensity exercise leads to cognitive benefits and modulation of MMP (see section 4.3) 
observed in RRMS patients, although study protocols have not been long enough (three weeks) 
to distinguish differences in clinical markers of RRMS disease activity (165). Of the RRMS 
exercise studies with extensive cytokine profiling, the study with the highest reported intensity 
also had the clearest discernible effect on inflammatory cytokines, including TNF-α, although 
findings in comparison to similar studies (but with slightly less intense protocols) are conflict-
ing (133,158). The potential reasons why there relatively sparse overlap between studies are 
many, including duration of effect after exposure, dosing and training protocols, selection of 
sample medium (i.e. plasma, serum, CSF or tissue), choice of biomarkers and assay sensitivity.  
Concerning the actual commonalities across exercise and DMF, as shown in Paper III and Pa-
per IV, there was little overt overlap with regards to cytokine profiles in plasma or CSF. We 
also compared immune protein profiles as measured on the same Olink™ panels in plasma and 
CSF between DMF treated RRMS patients and RRMS patients participating in an exercise 
intervention from a separate and previously published cohort (158). Overlapping immune pro-
tein markers between groups were relatively few and inconsistent, as shown in table 1. 
However, the main overlapping findings, as seen, include CCL4, FGF21, latency associated 
peptide (LAP)-TGF-β1 and TNF receptor super family 9 and will be further discussed with 
regards to their relevancy in an MS and exercise context.  
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Table 1. Comparison of differences in immune protein markers after dimethyl fumarate treatment and 
exercise in MS patients and aerobic exercise of moderate and high intensity in healthy participants. 
Protein  
biomarker 
MS DMF Running, intense Running, moderate MS exercise 
Plasma CSF Plasma CSF Plasma CSF Plasma CSF 
ADA  -       
CASP-8       -  
CCL4 +  +      
CCL11   +      
CD244       + + 
CD40  -     -  
CD5 - -       
CDCP1 + -       
CSF-1   +      
CST-5 -        
CX3CL1   +     + 
CXCL1       -  
CXCL6       -  
CXCL9 +        
EN-RAGE -      +  
FGF21 +  +      
FGF23 +        
FGF5  -       
FLT3L +       - 
IL-12B + -       
IL-17C -        
IL-18R1  -       
IL-7    +   -  
LAP-TGF-B-1  +     - + 
LIF-R   +      
MCP-1   +      
MCP-2       -  
MCP-4       -  
MMP-1       -  
MMP-10   + +     
OPG   +      
SIRT2       -  
ST1A1       -  
STAMPB       -  
TGF-A   +      
TNF-B  -       
TNFRSF14  -     -  
TNFRSF9 + - +      
TWEAK -        
UPA   +      
VEGF-A    +     
+: increased levels after intervention. -: decreased levels after intervention.  
 
CCL4, also known as macrophage inflammatory protein-1β, is a homing molecule for mono-
cytes among other immune cells who also can produce CCL4, of which neutrophils, T cells, B 
cells and fibroblasts among other cells are capable. In MS, CCL4 is predominantly found in 
parenchymal and perivascular macrophages that contain myelin degradation products and is 
assumed to promote disease activity through further leucocyte recruitment (183). It is also an 
important factor for T cell adhesion to vascular walls, necessary for cell migration (184). CCL4 
along with increases in IL-12 secretion from dendritic cells favor a Th1 response for parasite 
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clearing (185). Increased CCL4 levels in serum in isolation is seen with antibody-mediated 
demyelinating diseases but not MS (186). In combination with circulating (plasma) markers 
human growth factor, CCL11 and epidermal growth factor, however, it can be used to distin-
guish RRMS from SPMS and PPMS (187). Levels of CCL4 are generally lower in plasma of 
SPMS and PPMS patients compared to RRMS. The degree of inflammatory disease activity 
was not specified for these patients, but it opens up for speculation as to whether it might signify 
lower inflammatory, cell recruiting activity. CCL4 readily diffuses across experimental endo-
thelial monolayers, increasing vascular adhesion of activated CD4+ T cells and memory T cells 
(188). As primarily monocytes and lymphocytes are mobilized in both DMF treatment and 
transiently during physical exercise, increased CCL4 signaling is to be expected. However, 
CCL4 was not differentially increased in treatment responders on DMF in Paper III. 
TNF receptor super family 9, also named CD137, was increased in plasma of DMF and the 
intense running cohort but lowered in DMF CSF. CD137 functions as a costimulatory molecule 
on T cells. CD137 has been shown necessary for EAE development (189). Binding to CD137L, 
CD137 promotes IL-2 and -4 secretion and favor differentiation into CD8+ T cells. Prior studies 
show CD137 increased in serum and CSF of RRMS patients (190). Comparing plasma CD137 
levels in responders and non-responders to DMF treatment did not show significantly differing 
plasma levels of CD137. 
LAP-TGF-β1 was found to be increased in CSF in DMF treated RRMS patients and exercised 
RRMS patients. As measuring of TGF-β1 levels directly associated with low reliability, the 
more stable precursor form non-covalently bound to LAP is often preferred. Upon cleaving of 
LAP, TGF is activated. Interestingly, ROS exposure rapidly activates latent complex bound 
TGF-β (191). Clinical research on LAP-TGF-β1 is sparse but it has been reported to be in-
creased in RRMS patients receiving vitamin D-therapy, however, without any clear relation to 
effectiveness measures (192). Activated TGF-B facilitates remyelination, thus potentially of 
great benefit for MS patients (193). In EAE, TGF-β1 in combination with IL-6 promotes dif-
ferentiation of CD4+ T cells to Th17 cells (194). While the proinflammatory effect of the latter 
is consistent with described MS pathology, TGF-β1 serve beneficial functions. It is also one of 
two upregulated remyelination factors in the set of studies, drawing focus on the possible role 
of DMF in facilitating this. (For further investigation into this topic, see the thesis by Karl 
Carlström.) 
The perhaps most interesting factor increased by both DMF and high intensity running in 
plasma is FGF21, even if it was not increased in exercised RRMS patients. In a separate, non-
published analysis DMF treated RRMS patients had increased plasma levels of FGF21 by 14 
percent compared to baseline. FGF21 is a well-studied cytokine mainly secreted by the liver 
and contracting muscles. It functions as an important mediator in glucose and lipid metabolism 
in response to physiological stressors such as exercise and fasting (195,196). Although high 
peripheral levels of FGF21 have been associated with several metabolic diseases including di-
abetes type II, administration of FGF21 analogs improve the blood lipid profile in humans and 
improves insulin signaling and provides resistance to weight gain from overfeeding in mice 
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(197). Treatment of patients with diabetes type II with FGF21 is under development. FGF21 
has also been proposed as a regulator of oxidative stress as it increases the expression of anti-
oxidative enzymes such as superoxide dismutase 2 (198). Increased activity of Nrf2 is 
associated with higher peripheral levels of FGF21 in mice (199). Interestingly, peripherally 
derived FGF21 readily crosses the BBB and promotes proliferation in oligodendrocyte progen-
itor cells and subsequent remyelination through binding to B-klotho (200,201).  
In summary, though none of the differentially regulated biomarkers were consistent across all 
studies, the few overlapping protein markers highlight possible common mechanisms between 
exercise and DMF. Most prominent, perhaps, is FGF21 as a potential target for induction by 
DMF treatment and exercise, which could benefit neurological recovery in MS patients after 
manifest myelin and oligodendrocyte damage. This adds a second mechanism by which DMF 
treatment (and exercise) might benefit relapse recovery in MS, as Nrf2 increases expression of 
glutathione S-transferase 4α, which has been shown to benefit oligodendrocyte differentiation 
and remyelination (202). Beneficial effects from FGF21 also seem to pertain to diabetes type 
II, a common MS comorbidity as described in section 4.5. 
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10 CONCLUSIONS AND FUTURE PERSPECTIVES 
Following the four studies included in the thesis several conclusions on DMF in RRMS can be 
drawn: 
I) DMF is a moderately effective therapy in comparison to current treatment 
alternatives for RRMS patients both as initial and secondary therapy. 
II) The mode of action of DMF is partially related to monocyte counts and monocyte 
ROS production in interaction with lymphocytes in ways that potentially could be 
utilized in a clinical setting to distinguish patients responding to treatment from 
non-responders. 
III) Despite several mechanisms of DMF treatment overlap with that of intense aerobic 
exercise, there are few and inconsistent common denominators with regard to 
immune marker proteins. 
Further queries remain as to how DMF (and in extension pharmacological treatment) and ex-
ercise complement each other clinically, and if there are opportunities for synergistic effects on 
disease modulation and disease-related functional impairments. As exercise is shown benefi-
cial for several MS symptoms and common comorbidities and proven safe, clinical trials in 
combination with DMF and other DMTs would be both interesting from a research perspective 
and immediately useful for participating MS patients. Efforts to integrate exercise in MS treat-
ment are already ongoing, as described in section 6. As clinical effects are likely to require 
intervention periods of up to a year given adequate sample size, disease markers such as NFL, 
cell populations, cytokine profiles or epigenetic changes in immune cell subsets could be of 
value and require shorter interventions. 
Traditional RCTs are considered the gold standard for determining the risk-benefit of drugs. 
However, exceedingly large studies would be needed to compare across a number of therapies 
and different subpopulations of MS patients. In addition, the interest of doing such studies by 
the pharmaceutical industry is low and most patients are also unwilling to participate in trials 
with randomized treatments. Instead it is an important task for health authorities and academic 
research to device pragmatic studies in large real-world populations that collect multi-modal 
and detailed information on relevant effectiveness and adverse outcomes. This can be exem-
plified by the on-going prospective collection of data on patient treated with RTX and other 
treatment choices in COMBAT-MS, an observational drug trial funded by a federal US aca-
demic grant, comprising 3500 patients across all of Sweden. As more MS treatments are about 
to be introduced to market, evaluating the relative risk-benefit in an expedient manner is of 
great importance in order to improve both patient outcomes and cost-benefit. DMF, for exam-
ple, has two recently approved alternatives in monomethyl fumarate (Bafiertam™) and 
diroximel fumarate (Vumerity™). Both aim to mitigate the tolerability issues of DMF, poten-
tially making them more useful for newly diagnosed patients with a mild disease course. 
Despite much research is going into developing methods for effective drug repurposing, the 
serendipitous discovery of the benefits of DMF and RTX for MS highlight the inefficiencies 
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of this practice. Considering the clinical efficacy of RTX, earlier discovery would have been 
beneficial for MS patients on a large scale. With social security numbers and extensive and 
combinable registries on public health, Sweden is well-set for being the base for new such 
discoveries. Continued cross-disciplinary research and collaboration across clinics are likely to 
be key going forward in this endeavor. 
Further mechanistic studies are warranted to define the mechanism(s) of action of DMF so as 
to establish drug targets that are more specific. Research from our group has already partially 
explored this venue (203). With increased availability and utility of multi-omics (with its latest 
addition of the microbiome), as well as higher cellular resolution through single-cell sequenc-
ing, investigative studies on human samples are likely to yield more useful data. Handling and 
integrating data sets of this size require tools that are both in use and in rapid development, 
such as machine learning algorithms that can assess outcome relevant correlations from com-
plex data.  
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11 SIGNIFICANCE 
With increasing treatment options for RRMS patients, one of the main current challenges is to 
assess their comparative benefits, as well as identifying treatments that not only reduce inflam-
matory activity but also improve function and structural integrity of the CNS. Both DMF and 
rituximab represent alternatives that are superior in effectiveness to previously existing initial 
treatment choices for RRMS and a shift towards increasing early use of these therapies will be 
important to preserve neurological functions among newly diagnosed patients. Nonetheless, it 
is clear that they display different modes of action and further research will be needed to iden-
tify potential markers of beneficial treatment responses, including long term safety, in order to 
optimize drug tailoring and risk-benefit at the individual level. For manifest neurological defi-
cits, however, current DMTs have no proven effect, whereas accumulating evidence shows 
exercise to beneficial for a range of debilitating symptoms, including fatigue and motor deficits. 
Comorbidity, which adds additional burden of disease and may also worsen MS disease status, 
can also be alleviated through regular physical exercise. Despite this, the clinical use of exercise 
as a supplement to medical therapies is still scarce, likely as a consequence of still limited high 
quality studies, restricted mechanistic understanding of the effects and optimized training pro-
tocols for individual needs (121). Exercise intensity, for example, seems to have differential 
immunomodulatory benefits which is further explored within Paper IV. Potential common de-
nominators between DMTs and exercise on intrathecal inflammatory markers could also lead 
to better understanding of processes involved in the neurodegenerative aspects of the disease 
that are beyond most current drug therapies. In summary, combining the two approaches rep-
resented in this thesis work, namely optimizing early DMT and engaging in regular physical 
activity together with other life-style modifications likely improves chances of beneficial long-
term outcomes. The lack of obviously and consistently overlapping molecular pathways be-
tween DMF and physical activity when compared with protein markers suggests that one 
cannot substitute for the other and that there is an added benefit of combining them. For pa-
tients, the benefits are likely to be manifold both in the long and short term, not only delaying 
MS disease progression, but also reducing the risk of comorbidity. Together this can help our 
patients preserve as much of their full potential in life. 
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